ПАНКРЕАТИЧЕСКИЕ ЗВЕЗДЧАТЫЕ КЛЕТКИ: СТРУКТУРА И ФУНКЦИЯ. ЧАСТЬ II. АКТИВИРОВАННЫЕ ПАНКРЕАТИЧЕСКИЕ ЗВЕЗДЧАТЫЕ КЛЕТКИ
Аннотация
В обзоре представлен анализ литературных сведений об активированных звездчатых клетках поджелудочной железы. Показаны факторы, способствующие их активации. Детализированы специфические структурно-функциональные признаки активированных панкреатических звездчатых клеток: отсутствие витамин А-содержащих липидных капель в цитоплазме; экспрессия а-гладкомышечного актина; избыточный синтез и накопление белков внеклеточного матрикса; усиленная пролиферация и миграция; секреция цитокинов, хемокинов и ростовых факторов. Обсуждаются механизмы активации звездчатых клеток и возможность регуляции этого процесса.
Литература
1. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, Garcia-Munoz B, Gonzalez-Grande R, Pizarro A, Duran JA, Jimenez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmeron J, Martin-Vivaldi R. Drug-induced liver injures analisis of 461 residences submitted to the Spanish registry a 10-years period. Gastroenterol. 2005;129:512-521. doi: 10.1016/j.gastro.2005.05.006.
2. Hazanov AI, Rumjancev ON, Kalinin AV. Osobennosti lekarstvennyh i virusno-lekarstvennyh porazhenij pecheni [Peculiaritits of iatrogenic and viral-iatrogenic liver damages]. Kremlevskaja medicina. 2000;1:44-47. (Russian).
3. Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000;84:1275-1311.
4. Sherlok Sh, Duli Dzh. Zabolevanija pecheni i zhelchnyh putej. Moscow: Gjeotar medicina; 1999. 859 p. (Russian).
5. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol. 2005;33(1):155-164. doi: 10.1080/01926230590522356.
6. Dossing M, Sonne J. Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf. 1993;9(6):441-449. doi: 10.2165/00002018-199309060-00007.
7. Chang CY, Schiano TD. Review article: drug hepatotoxicity. Alimentary pharmacology & therapeutics. 2007;25(10):1135-1151. doi 10.1111/j.1365-2036.2007.03307.
8. Thiim M, Friedman LS. Hepatotoxicity of antibiotics and antifungals. Clin Liver Dis. 2003;7(2):381-399.
9. Bueverov AO. Lekarstvennye porazhenija pecheni. RMZh Gastrojenterologija. 2001;9:13-15. (Russian).
10. Larrey D. Drug-induced liver disease. J.Hepatol. 2000;32(Suppl 1):77-88.
11. Buratti S, Lavine JE. Drugs and the liver: advances in metabolism, toxicity, and therapeutics. Curr Opin Pediatr. 2002;14:601-607.
12. Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality? Pharmacoepidemiology and Drug Safety. 2011;20(6):567-582. doi: 10.1002/pds.2127.
13. Marschall HU, Wagner M, Zollner G, Trauner M. Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. Mol Pharm. 2007;4(6):895-910. doi: 10.1021/mp060133c.
14. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis. 2000;4(1):73-96.
15. Beninchou C. Criteria of drug-induced liver disorder. Report of an international consensus meeting. J. Hepatol. 1990;11(2):272-276.
16. Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, Garcia-Cortes M, Fernandez MC, Pelaez G, Rodrigo L, Duran JA, Costa J, Planas R, Barriocanal A, Guarner C, Romero-Gomez M, Munoz-Yague T, Salmeron J, Hidalgo R. Outcome of acute idiosyncratic drug induced liver injury. J. Hepatol. 2006;44(6):1581-1588. doi: 10.1002/hep.21424.
17. Andrade RJ, Agundez JA, Lucena MI, Martinez C, Cueto R, Garcia-Martin E. Pharmacogenomics in drug induced liver injury. Curr Drug Metab. 2009;10(9):956-970.
18. Lucena MI, Garcia-Martin E, Andrade RJ, Martinez C, Stephens C, Ruiz JD, Ulzurrun E, Fernandez MC, Romero-Gomez M, Castiella A, Planas R, Duran JA, De Dios AM, Guarner C, Soriano G, Borraz Y, Agundez JA. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology. 2010;52(1):303-312. doi: 10.1002/hep.23668.
19. Bjornsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scandinavian J Gastroenterology. 2005;40(9):1095-1101. doi: 10.1080/00365520510023846.
20. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Internal Med. 2002;137(12):947-954.
21. Lucena MI, Kaplowitz N, Hallal H, Castiella A, Garcia-Bengoechea M, Otazua P, Berenguer M, Fernandez MC, Planas R, Andrade RJ. Recurrent Drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011;55(4):820-827. doi: 10.1016/j.jhep.2010.12.04.
22. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6(3):755-774.
23. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis. 2002;22(2):185-194. doi: 10.1055/s-2002-30106.
24. Kaplowitz N. Drug induced hepatitis. In: Diel M, Hayashi N, Manns MP, eds. Chronic hepatitis: metabolic, cholestatic, viral and autoimmune. Dordrecht: Springer; 2007. p. 32-42.
25. Hazanov AI. Ostryj lekarstvennyj gepatit. In: Kalinina AV, Hazanova AI, eds. Gastrojenterologija i gepatologija: diagnostika i lechenie. Moscow: Miklosh; 2007. p. 416-420. (Russian).
26. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, Garcia-Munoz B, Gonzalez-Grande R, Pizarro A, Duran JA, Jimenez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmeron J, Martin-Vivaldi R. Drug-induced liver injures analisis of 461 residences submitted to the Spanish registry a 10-years period. Gastroenterol. 2005;129:512-521. doi: 10.1016/j.gastro.2005.05.006.
27. Zimmerman H, Yeviqah JH. Drug induced cholestasis. Baillieries Clin. Gastroenterol. 1998;2:423-452.
28. Chitturi S, Farrell G. Drug-induced cholestasis. Semin Gastrointest Dis. 2001;122:113-24.
29. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J. Hepatol. 1990;11(2):272-276.
30. Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol. 1997;26(Suppl 2):12-21.
31. Zhang W, Parentau H, Greenly RL, Metz CA, Aggarwal S, Wainer IW, Tracy TS. Effect of protein-calorie malnutrition on cytochromes P450 and glutathione S-transferase. Eur J Drug Metab Pharmacokinet. 1999;24:141-147. doi: 10.1007/BF03190359.
32. Teschke R. Drug-induced liver diseases. Z Gastroenterol. 2002;40(5):305-326. doi: 10.1055/s-2002-30118.
33. Lucena MI, Andrade RJ, Martinez C, Ulzurrun E, Garcia-Martin E, Borraz Y, Fernandez MC, Romero-Gomez M, Castiella A, Planas R, Costa J, Anzola S, Agundez JA. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology. 2008;48(2):588-596. doi: 10.1002/hep.22370.
34. Lucena MI, Andrade RJ, Kaplowitz N, Garcia-Cortes M, Fernandez MC, Romero-Gomez M, Bruguera M, Hallal H, Robles-Diaz M, Rodriguez-Gonzalez JF, Navarro JM, Salmeron J, Martinez-Odriozola P, Perez-Alvarez R, Borraz Y, Hidalgo R. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49(6):2001-2009. doi: 10.1002/hep.22895.
35. Andrade RJ, Lucena MI, Alonso A, Garcia-Cortes M, Garcia-Ruiz E, Benitez R, Fernandez MC, Pelaez G, Romero M, Corpas R, Duran JA, Jimenez M, Rodrigo L, Nogueras F, Martin-Vivaldi R, Navarro JM, Salmeron J, de la Cuesta FS, Hidalgo R. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology. 2004;39(6):1603-1612. doi: 10.1002/hep.20215.
36. Adukauskiene D, Dockiene I, Naginiene R, Kevelaitis E, Pundzius J, Kupcinskas L. Acute liver failure in Lithuania. Medicina. 2008;44(7):536-540.
37. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806-815. doi: 10.1038/clpt.2011.58.
38. Novikov VE, Klimkina EI. Farmakologija gepatoprotektorov. Obzory po klinicheskoj farmakologii i lekarstvennoj terapii [Reviews on Clinical Pharmacology and Drug Therapy]. 2005;4(1):2-20. (Russian).
39. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481-489. doi: 10.1002/hep.20800.
40. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135(6):1924-1934. doi: 10.1053/j.gastro.2008.09.011.
2.png)
